<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table4" position="float"><label>Table 4.</label><caption><title>Geometric means of viable tumor residues after treatment of cTACE or TILA-TACE in the RCT.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th colspan="2" valign="top">Geometric mean (95% CI)</th><th valign="top"/></tr><tr><th valign="top"/><th valign="top">cTACE (n=10)</th><th valign="top">TILA-TACE (n=10)</th><th valign="top">p value</th></tr></thead><tbody><tr><td valign="top">Crude VTR</td><td valign="top">25.4% (10.1%&#8211;64.0%)</td><td valign="top">4.6 (1.8%&#8211;11.4%)</td><td valign="top">0.008</td></tr><tr><td valign="top">Multivariable adjusted VTR*</td><td valign="top">28.1% (13.9%&#8211;56.8%)</td><td valign="top">4.1 (2.0%&#8211;8.4%)</td><td valign="top">0.0009</td></tr></tbody></table><table-wrap-foot><fn><p>VTR: viable tumor residues;</p><p>cTACE: transarterial chemoembolization;</p></fn><fn><p>TILA-TACE: targeting-intratumoral-lactic-acidosis TACE;</p><p>RCT: randomized clinical trial.</p></fn><fn><p>*Adjusted for viable tumor volume prior to treatment using the general linear regression. No appreciable alterations in results were found after adjusting for other covariates such as age, BCLC tumor stage, extra-hepatic metastasis, HBV DNA copy numbers, macrovascular invasion, and tumor multifocality individually.</p></fn></table-wrap-foot></table-wrap>